Should a young adult male patient with Philadelphia-like ALL being treated on the Alliance A041501 protocol and in remission undergo transplant?
Transplant is not part of the trial but is the standard outside of the trial. A041501 is a phase III trial to evaluate the efficacy of the addition of Inotuzumab Ozogamicin (a conjugated anti-CD22 monoclonal antibody) to frontline therapy in young adults (ages 18-39 years) with newly diagnosed precursor B-Cell ALL.
Answer from: Medical Oncologist at Academic Institution
I would offer transplant. Ph-like ALL usually carries a poor prognosis and has been associated with worse overall survival and event-free survival compared to patients with other non-Philadelphia positive B-ALL (with approximately 5-year survival of 23% versus 59% according to a study by MD Anderson...
Sign in or Register to read more